Prussian blue nanozyme with near-infrared heat to heal severe radiation dermatitis after head and neck radiotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Severe (Grade III) radiation dermatitis after head and neck radiotherapy can be hard to treat, and this approach combines a Prussian blue–based nanozyme with near‑infrared (NIR) thermotherapy to speed healing. Prussian blue is formulated as a photo‑responsive nanozyme intended to scavenge reactive oxygen species at the injury site and reduce inflammation. During treatment, the nanozyme is applied to the lesion and NIR light is used to trigger local thermal and therapeutic effects to promote tissue repair. The trial will enroll appropriate patients receiving high‑dose radiotherapy and monitor skin healing, safety, and symptom improvements.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with a pathological diagnosis of non-metastatic head and neck malignant tumors;
2. Patients deemed suitable for high-dose radiotherapy, either as a primary treatment or as postoperative treatment following surgical resection.

Exclusion Criteria:

1. Eastern Cooperative Oncology Group performance status of \>2;
2. Pre-existing skin rash, ulceration or open wound in the treatment area;
3. Known allergy to trolamine or prussian blue;
4. Inflammatory or connective tissue disorder of the skin;
5. History of head and neck radiotherapy.

Where it's running

• Sichuan University West China Hospital
  Chengdu, Sichuan, China Recruiting

Study contacts

• Principal investigator: Xingchen Peng — Sichuan University West China Hospital
• Study coordinator: Xingchen Peng
• Email: pxx2014@163.com
• Phone: +86 18980606753

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adapalene gel vs. Biafine for acute radiation dermatitis in adults receiving radiotherapy

  A gel containing adapalene is being tested to see if it helps with skin injury from radiation compared with Biafine in adults undergoing radiotherapy.

  Recruiting Early Phase 1 Yunnan Cancer Hospital · Kunming, Yunnan · NCT07886320

• Mepitel Film for Preventing Radiation Dermatitis in Breast Cancer Patients in Singapore

  This observational study tests whether Mepitel Film can help prevent radiation dermatitis in breast cancer patients getting whole breast or chest wall radiotherapy in Singapore.

  Recruiting National University Hospital, Singapore · Singapore · NCT07729423

• Amino acid–derived antioxidant lipids to prevent and treat radiation skin damage in head and neck cancer

  This trial will try a new amino acid–based lipid treatment that soaks up harmful reactive oxygen species to prevent or lessen radiation dermatitis in people receiving high‑dose radiotherapy for head and neck cancer.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07081074

• Skin-repair cream to prevent radiation dermatitis after breast cancer surgery

  This phase 3 trial tests whether a natural weak-acid skin repair cream can prevent acute radiation dermatitis in adults who had mastectomy and are receiving adjuvant radiotherapy for breast cancer.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07066280

• ROS-scavenging nanoenzyme prevention for radiation dermatitis in head and neck cancer

  This trial will try to see if giving novel ROS-scavenging nanoenzymes can prevent radiation-related skin damage in people receiving high-dose radiotherapy for head and neck cancer.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07064577

• Comparing Betamethasone and Moisturizer for Skin Care in Breast Cancer Patients

  This study is testing whether a skin cream called betamethasone can help prevent skin problems from radiation therapy in large-breasted breast cancer patients compared to using just a moisturizer.

  Recruiting Phase 3 Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT06915857

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.